Nikki March

Dr March is a cancer biologist with special interests in cell signaling, intestinal oncology, and drug discovery. Her PhD research at the University of Cambridge examined the regulation of AP-1 proteins by MAP kinase pathways, and she has more than 22 years of broad experience in the oncology field, mostly gained in academia but more recently in biotech. She is currently Senior Director of Scientific Affairs at Cumulus Oncology, where she builds new assets in drug discovery. She also sits on the Scientific Advisory Board of Carcinotech, a 3D tumor bioprinting company. She specializes in target identification and validation, and previously led the Target Validation group of the Drug Discovery Unit at Cancer Research UK Manchester Institute. Prior to this, she was a Senior Research Fellow at Cancer Research UK Cambridge Institute, where she worked in collaboration with the Sanger Institute and the Netherlands Cancer Institute to develop innovative transgenic models to identify and characterize novel driver genes in colorectal cancer. Dr March was also a Postdoctoral Research Scientist at the Babraham Institute, UK, where, in collaboration with UCB Pharma, she studied the mode of action of an anti-epilepsy drug. She regularly gives invited lectures both nationally and internationally and has published in various international peer-reviewed journals. Dr March joined Edanz as an editor in 2011.